<DOC>
	<DOCNO>NCT01022346</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel arm study assess safety efficacy RO5217790 histologic resolution participant high grade CIN associate HR-HPV infection . Participants randomize receive 3 subcutaneous injection either placebo RO5217790 Days 1 , 8 , 15 . Study assessment make Baseline , Month 3 6 , every 6 month thereafter overall 2.5 year .</brief_summary>
	<brief_title>A Study RO5217790 Participants With High Grade Cervical Intraepithelial Neoplasia ( CIN ) Associated With High Risk Human Papillomavirus ( HR-HPV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<criteria>Have diagnosis within 2 month prior first dose RO5217790 CIN 2/3 confirm colposcopydirected punch biopsy ; patient must least 1 quadrant residual CIN2/3 disease remain biopsy . Entry trial allow base local assessment criterion ; however , CIN 2/3 diagnosis confirm central pathologist purpose analyze study Have satisfactory colposcopy , i.e . entire acetowhite disease area well entire squamocolumnar junction visualize colposcopy Have detection screen single multiple HRHPV infection analysis liquid base cytology ( LBC ) material Roche Linear Array assay consistent trial stratum specify study protocol Have colposcopically visible CIN2/3 disease extend 2 quadrant Have anatomical condition cervix , include result previous cervical surgery , congenital malformation condition , would interfere complete evaluation transformation zone surveillance CIN . If endocervical curettage ( ECC ) perform , endocervical curettings reveal CIN , patient eligible long endocervical lesion directly extend primary lesion colposcopically visible entirety Have vulvar ( VIN ) vaginal ( VAIN ) intraepithelial neoplasia Have atypical endometrial glandular cell evidence carcinoma biopsy Have serious , concomitant disorder , include active systemic infection require treatment Have prior history current malignancy adequately treat skin cancer ( squamous cell cancer basal cell carcinoma ) , unless history skin cancer site study treatment administration Have proven suspect immunosuppressive disorder autoimmune disease Have significant cardiac , hepatic renal disease Have active viral infection include human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis B virus ( HBV ) , cytomegalovirus ( CMV ) , Epstein barr virus ( EBV ) within 30 day receive study treatment . Mild viral infection Herpes Simplex Virus 1 ( HSV1 ) common cold exclude</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cervical intraepithelial neoplasia</keyword>
	<keyword>RO5217790</keyword>
</DOC>